Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells

Endocrinology

Volumn 140, Issue 1, 1999, Pages 416-421

  Lapointe, Jacques ^a   Fournier, Andréa ^a   Richard, Virgile ^a   Labrie, Claude ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ESTRADIOL; ESTROGEN; HYDROXYFLUTAMIDE; MESSENGER RNA;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; DOSE TIME EFFECT RELATION; DRUG MECHANISM; FEMALE; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

EID: 0032894681     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.1.6410     Document Type: Article

References (45)

1. 1. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ 1984 Androgen receptors in breast cancer. Cancer 54:2436-2440
2. 2. Lea OA, Kvinnsland S, Thorsen T 1989 Improved measurement of androgen receptors in human breast cancer. Cancer Res 49:7162-7167
3. 3. Soreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S 1992 Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol 18:112-118
4. 4. Fels E 1944 Treatment of breast cancer with testosterone proprionate. A preliminary report. J Clin Endocrinol 4:121-125
5. 5. Cooperative Breast Cancer Group 1964 Testosterone propionate therapy of breast cancer. JAMA 188:1069-1072
6. 6. Segaloff A, Gordon D, Horwitt BN, Schlosser JV, Muroson PJ 1951 Hormonal therapy in the cancer of the breast. I. The effect of testosterone propionate therapy on clinical course and hormonal excretion. Cancer 4:319-323
7. 7. Kennedy BJ 1958 Fluoxymesterone therapy in treatment of advanced breast cancer. N Engl J Med 259:673-675
8. 8. Tormey DC, Lippman ME, Edwards BK, Cassidy JG 1983 Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 98:139-144
9. 9. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, Tschetter LK, Long HJ, Gerstner JG, Windschitl HE, Levitt R, Pfeifle DM 1991 Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer 67:886-891
10. 10. Gordan GS, Halden A, Horn Y, Fuery JJ, Parsons RJ, Walter RM 1973 Calusterone (7β,17α-dimethyltestosterone) as primary and secondary therapy of advanced breast cancer. Oncology 28:138-146
11. 11. Poulin R, Baker D, Labrie F 1988 Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat 12:213-225
12. 12. Simard J, Hatton AC, Labrie C, Dauvois S, Zhao HF, Haagensen DE, Labrie F 1989 Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells. Mol Endocrinol 3:694-702
13. 13. Poulin R, Simard J, Labrie C, Petitclerc L, Dumont M, Lagace L, Labrie F 1989 Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. Endocrinology 125:392-399
14. 14. Simard J, Dauvois S, Haagensen DE, Levesque C, Merand Y, Labrie F 1990 Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. Endocrinology 126:3223-3231
15. 15. de Launoit Y, Dauvois S, Dufour M, Simard J, Labrie F 1991 Inhibition of cell cycle kinetics and proliferation by the androgen 5α-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[16'α-chloro-3',17β-dihydroxy-estra-1',3',5'-(10')triene-7'α-yl] undecanamide in human breast cancer ZR-75-1 cells. Cancer Res 51:2797-2802
16. 16. Hackenberg R, Luttchens S, Hofmann J, Kunzmann R, Holzel F, Schulz KD 1991 Androgen sensitivity of the new human breast cancer cell line MFM-223. Cancer Res 51:5722-5727
17. 17. Labrie F, Simard J, de Launoit Y, Poulin R, Theriault C, Dumont M, Dauvois S, Martel C, Li S M 1992 Androgens and breast cancer. Cancer Detect Prev 16:31-38
18. 18. Simard J, de Launoit Y, Haagensen DE, Labrie F 1992 Additive stimulatory action of glucocorticoids and androgens on basal and estrogen-repressed apolipoprotein-D messenger ribonucleic acid levels and secretion in human breast cancer cells. Endocrinology 130:1115-1121
19. 19. Blais Y, Sugimoto K, Carriere MC, Haagensen DE, Labrie F, Simard J 1994 Potent stimulatory effect of interleukin-1α on apolipoprotein D and gross cystic disease fluid protein-15 expression in human breast-cancer cells. Int J Cancer 59:400-407
20. 20. Dauvois S, Geng CS, Levesque C, Merand Y, Labrie F 1991 Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res 51:3131-3135
21. 21. Thompson CB 1995 Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-1462
22. 22. Kroemer G 1997 The proto-oncogene Bcl-2 and its role in regulating apoptosis [published erratum appears in Nat Med 3:934, 1997]. Nat Med 3:614-620
23. 23. Reed JC 1997 Double identity for proteins of the Bcl-2 family. Nature 387:773-776
24. 24. Levesque C, Merand Y, Dufour JM, Labrie C, Labrie F 1991 Synthesis and biological activity of new halo-steroidal antiestrogens. J Med Chem 34:1624-1630
25. 25. Labrie C, Martel C, Dufour JM, Levesque C, Merand Y, Labrie F 1992 Novel compounds inhibit estrogen formation and action. Cancer Res 52:610-615
26. 26. Teixeira C, Reed JC, Pratt MA 1995 Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55:3902-3907
27. 27. Tsujimoto Y, Cossman J, Jaffe E, Croce C M 1985 Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443
28. 28. Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P, Korsmeyer SJ 1988 Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-lg fusion gene in lymphoma. EMBO J 7:123-131
29. 29. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, Korsmeyer SJ 1989 bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79-88
30. 30. McDonnell TJ, Nunez G, Platt FM, Hockenberry D, London L, McKearn JP, Korsmeyer SJ 1990 Deregulated Bcl-2-immunoglobulin transgene expands a resting but responsive immunoglobulin M and D-expressing B-cell population. Mol Cell Biol 10:1901-1907
31. 31. McDonnell TJ, Korsmeyer SJ 1991 Progression from lymphoid hvperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 349:254-256
32. 32. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ 1990 Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336
33. 33. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ 1991 BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88:6961-6965
34. 34. Lu QL, Poulsom R, Wong L, Hanby AM 1993 Bcl-2 expression in adult and embryonic non-haematopoietic tissues. J Pathol 169:431-437
35. 35. Bhargava V, Kell DL, van de Rijn M, Warake RA 1994 Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 145:535-540
36. 36. Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A, Bhalla K 1997 Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 42:73-81
37. 37. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R 1995 Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55:4438-4445
38. 38. Dorai T, Goluboff ET, Olsson CA, Buttyan R 1997 Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents. Anticancer Res 17:3307-3312
39. 39. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML 1992 Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944
40. 40. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP 1995 Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 55:735-738
41. 41. Neri R, Florance K, Koziol P, Van Cleave S 1972 A biological profile of a nonsteroidal antiandrogen, SCH 13521 (4'-nitro-3'-trifluoromethylisobutyranilide). Endocrinology 91:427-437
42. 42. Poyet P, Labrie F 1985 Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol 42:283-288
43. 43. Luthy IA, Begin DJ, Labrie F 1988 Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem 31:845-852
44. 44. Marchetti B, Labrie F 1988 Characteristics of flutamide action on prostatic and testicular functions in the rat. J Steroid Biochem 29:691-698
45. 45. Labrie C, Simard J, Zhao HF, Pelletier G, Labrie F 1990 Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate. Mol Cell Endocrinol 68:169-179